Study of Plozasiran in Adults With Severe Hypertriglyceridemia
NCT06347016 · SHASTA-4 Phase 3Completed
- Lead sponsor
- Arrowhead Pharmaceuticals (Industry)
- Enrollment
- 311 (actual)
- Start date
- 23 Jul 2024
- Primary completion
- 17 Jun 2026 (actual)
- Study completion
- 10 Sep 2026
- Last update posted
- 9 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Plozasiran Injection Drug
- Placebo Drug
Conditions and primary outcome
- Severe Hypertriglyceridemia
Primary outcome
Percent change in fasting serum TG levels from baseline to Month 12 compared to placebo (Baseline, Month 12)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedPlozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis.
The New England journal of medicine · 2026 Nov 5
PubMed 42981569 (opens in a new tab)DOI 10.1056/NEJMoa2610014 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06347016 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.